Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

538 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19.
Spagnuolo V, Guffanti M, Galli L, Poli A, Querini PR, Ripa M, Clementi M, Scarpellini P, Lazzarin A, Tresoldi M, Dagna L, Zangrillo A, Ciceri F, Castagna A; COVID-BioB study group. Spagnuolo V, et al. Sci Rep. 2021 May 17;11(1):10699. doi: 10.1038/s41598-021-89270-9. Sci Rep. 2021. PMID: 34001918 Free PMC article. No abstract available.
Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2).
Maggiolo F, Gianotti N, Comi L, Di Filippo E, Fumagalli L, Nozza S, Galli L, Valenti D, Rizzi M, Castagna A. Maggiolo F, et al. Among authors: fumagalli l. J Antimicrob Chemother. 2020 May 1;75(5):1332-1337. doi: 10.1093/jac/dkaa018. J Antimicrob Chemother. 2020. PMID: 32129855 Clinical Trial.
Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial.
Maggiolo F, Gianotti N, Comi L, Di Filippo E, Fumagalli L, Nozza S, Galli L, Valenti D, Rizzi M, Castagna A. Maggiolo F, et al. Among authors: fumagalli l. Antivir Ther. 2021 May;26(3-5):51-57. doi: 10.1177/13596535211042226. Epub 2021 Oct 27. Antivir Ther. 2021. PMID: 35485333 Clinical Trial.
Infections occurring in adult patients receiving mechanical circulatory support: the two-year experience of an Italian National Referral Tertiary Care Center.
Pieri M, Agracheva N, Fumagalli L, Greco T, De Bonis M, Calabrese MC, Rossodivita A, Zangrillo A, Pappalardo F. Pieri M, et al. Among authors: fumagalli l. Med Intensiva. 2013 Oct;37(7):468-75. doi: 10.1016/j.medin.2012.08.009. Epub 2012 Oct 3. Med Intensiva. 2013. PMID: 23040766 Free article. English, Spanish.
538 results